Gavin Gear
Chief Executive Officer & Owner LOGIX BIOSCIENCES
As Founder and CEO, Gavin leads the team behind a patented composition engineered to tackle a global healthcare crisis: antimicrobial resistance. By combining an evolution-blocking mechanism with targeted mucosal delivery, the platform creates a structural dead end for the pathogen at its primary point of entry. Seeking strategic partnerships and supported by top-tier FDA regulatory and commercialization experts, Gavin is advancing this technology into clinical reality—stopping bacterial adaptation where it starts to usher in an era of permanent therapeutic efficacy.
Seminars
Thursday 4th February 2027
Expanding the Therapeutic Potential of Intranasal Delivery: From Immune Modulation to Next-Generation Anti-Infectives
9:30 am
- Explore how intranasal delivery is creating new opportunities for immune modulation, infectious disease prevention, and treatment beyond traditional symptomatic therapies
- Understand how local nasal delivery can improve therapeutic effectiveness while reducing systemic exposure and minimizing development challenges associated with conventional administration routes
- Evaluate emerging strategies being used to address antimicrobial resistance and respiratory health through innovative intranasal therapeutic platforms
